Clinical relevance of partial HPV genotyping in cervical cancer screening

部分HPV基因分型在宫颈癌筛查中的临床意义

阅读:1

Abstract

Partial human papillomavirus (HPV) genotyping is increasingly used to triage high-risk (HR)-HPV-positive women in national cervical cancer screening. This study evaluated whether separate triage for HPV genotypes 16 and 18 could enhance the effectiveness of Finland's program. Data from 76,482 women participating in primary HPV screening in Tampere and surrounding municipalities (2012-2023) were analyzed. Partial genotyping identified HPV16, HPV18, and 12 other HR-HPV-types, and the association between genotype and high-grade squamous intraepithelial lesions or worse (HSIL +) detection was assessed. Among 6031 HR-HPV-positive women, HSIL + prevalence was highest in HPV16-positive women (37.3%) followed by HPV18 (26.0%) and other HR-HPV types (20.3%). HSIL + detection declined with age: 26.2%(age < 45), 15.9%(age 45-50), and 11%(age > 50)(p < 0.001). HPV16 showed the highest persistence upon re-testing (69.6% single; 84.6% co-infections), compared to 53.8% for other HR-HPV types. Among women with NILM cytology, HPV16 infections conferred a significantly higher risk of HSIL + compared to infections with other HR-HPV types. This risk was evident for both single HPV16 infection (OR 2.41;95%CI:1.55-3.75) and HPV16 coinfections (OR 3.86;95%CI:2.14-6.96). These findings support the integration of age-specific strategies and partial HPV16/18 genotyping into Finland's screening program. A refined triage model, including immediate colposcopy referral for HPV16/18-positive women, could improve patient management and screening efficiency.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。